RADx Tech II: Fast-Track Program to Advance U.S. COVID-19 Testing Capabilities - POCTRN
In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADxsm) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.
null RADx Tech II: Fast-Track Program to Advance U.S. COVID-19 Testing Capabilities
RADx Tech II: Fast-Track Program to Advance U.S. COVID-19 Testing Capabilities
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is announcing today that its Point-of-Care Technology Research Network (POCTRN) is soliciting proposals to further advance SARS-CoV-2 testing technologies in order to fill specific unmet national needs. Unmet needs include but are not limited to point-of-care/over-the-counter tests with lab performance, tests for multiple pathogens, and tests adaptable to emerging variants.
Rapid Acceleration of Diagnostics (RADx) is a fast-track program that leverages POCTRN. This solicitation will only consider proposals for technologies in an advanced stage of readiness that can reach the market in 2021.
To meet the accelerated timelines, RADx has assembled a national network of expert technical, clinical, manufacturing, and regulatory advisors who will provide individualized assistance for funded projects. NIBIB will provide financial and in-kind support to accelerate commercialization of projects that successfully meet aggressive milestones. To ensure that innovations are available to the public as quickly as possible, NIH will leverage established partnerships with federal agencies, such as FDA, CDC, CMS, and ASPR/BARDA, as well as commercial and private entities, to propel technologies developed by RADx into widespread use.